By Ram Khandelwal — Cardiac survivor, Founder & CEO, Heart Health India Foundation (HHIF)
This is the case for social prescribing in India — and why, for heart patients, connection is as vital as any medicine.
In December 2019, a cardiologist handed me a discharge summary, a strip of medicines, and a follow-up date. What that piece of paper did not contain — could not contain — was the harder half of my recovery. I was 33. Nobody prescribed me a way to manage the fear that arrived at 2 a.m. Nobody prescribed me a peer who had survived what I had survived. Nobody asked whether my wife, suddenly a full-time caregiver, was coping — though, as we would later write about the invisible weight caregivers carry, she was quietly checking, worrying, and absorbing it all alone. The clinical system had done its job brilliantly. The human system around the disease had been left entirely to chance.
That gap is what social prescribing is built to close. And for a country carrying one-fifth of the world’s cardiovascular deaths, closing it is not a wellness luxury. It is a survival strategy.
What is social prescribing?
Social prescribing is a simple but radical idea: that a doctor, nurse, or community health worker can formally “prescribe” not just drugs but connection — referring a patient to non-clinical, community-based support that addresses the social roots of ill health. A link worker (sometimes called a community connector) sits between the clinic and the community, takes the time to understand what actually matters to a patient, and links them to services: peer support groups, supervised exercise, financial counselling, nutrition guidance, mental-health support, or simply companionship.
For a chronic condition like cardiovascular disease, the most powerful of those community assets are not built by the health system at all — they are built by patients. Peer support, where a fellow cardiac patient becomes a mentor; patient and caregiver education delivered by people who have lived the diagnosis; and patient advocacy by the patients, for the patients — these are the substance of the social prescription, not its soft accompaniment. At HHIF, this is not theory but our daily work: Monthly Heart Circles and post-discharge follow-up calls, an “Ask An Expert” service connecting patients to cardiologists, and a Facebook and WhatsApp network of over 4,000 heart patients and caregivers — one of India’s largest online heart-support communities. The advocate with lived experience, whether a survivor or a caregiver, is not a volunteer doing charity. They are a node in the health system. When a country embeds them deliberately, it is not being kind; it is building a more resilient health system — one that can absorb a chronic-disease load no number of cardiologists could carry alone.
The World Health Organization, in A Toolkit on How to Implement Social Prescribing, frames it precisely this way — a means of connecting patients to a range of non-clinical services in the community to improve their health and well-being, built on the evidence that social determinants such as income, social inclusion, housing, and education are decisive in health outcomes. WHO’s companion philosophy in Community Engagement: A Health Promotion Guide for Universal Health Coverage in the Hands of the People makes the deeper point: health is not something delivered to communities; it is something built with and by them. Social prescribing is the operational bridge between those two documents — it puts a slice of the health system back into the hands of the people.
The questions that build understanding
The best way to understand social prescribing is not to memorise a definition but to sit with the questions a thoughtful clinician — or a frightened patient — would actually ask. The answers, taken together, are the whole concept.
If the medicine is correct, why isn’t the patient getting better?
This is the question that starts everything. Across the world, an estimated 80% of a person’s health outcomes are shaped by factors outside the clinic — behaviour, environment, social and economic circumstances. You can stent an artery in ninety minutes; you cannot stent loneliness, poverty, or a sedentary life with a catheter. For cardiovascular disease, where recovery is measured in years of adherence rather than a single procedure, the non-clinical determinants are the disease management. Social prescribing exists because we finally admitted that the prescription pad was only treating half the patient.
So what is actually being “prescribed”?
Not a drug — a connection. At its heart sit three moving parts: someone who notices the non-medical need (a clinician or health worker), someone who navigates it (a link worker or community connector), and somewhere to go (a community asset — a peer group, an exercise programme, financial counselling, a listening ear). The prescription is the deliberate act of writing that connection into the patient’s care, rather than leaving them to find it by luck.
Who is this for, and who does the prescribing?
It is for patients whose needs are chronic, recurring, or socially complex — and cardiac patients sit squarely in that group. Crucially, the prescriber need not be a cardiologist. A GP can do it, an ASHA or ANM worker can do it, a trained survivor can do it. And the community asset they prescribe into is increasingly staffed by patients themselves — fellow cardiac patients serving as mentors, caregivers educating newer caregivers, lived-experience advocates translating a diagnosis into a survivable daily routine. The connectors need not be doctors at all. That is precisely why social prescribing scales in low-resource settings where specialists are scarce but community is abundant: it turns the people who already carry the disease into part of the workforce that manages it.
Where and when does it happen?
In the community — primary health centres, urban health posts, residential welfare associations, places of worship, workplaces, and increasingly on the phone in a patient’s hand. WHO is explicit that there is no single blueprint; the scheme is shaped to local context. And it happens precisely at the moments patients fall through the cracks: at discharge, through the fragile first ninety days after a cardiac event, at a new diagnosis, and across the long, quiet plateau of lifelong medication when most people are left entirely alone.
And how do you actually build one?
WHO’s toolkit answers this with a clear sequence: assemble an implementation team and win leadership buy-in; understand and segment the target population, including their income profile and digital literacy; write a workplan that defines roles for clinicians, link workers, and community organisations; then pilot, deliver, monitor, and evaluate. The quiet genius of the method is its modularity — you can begin with a single clinic and a single link worker, and grow from there.
Why social prescribing is non-negotiable for India’s cardiac patients
Consider the numbers. India accounts for roughly one-fifth of global CVD deaths, and a recent meta-analysis pooling 25 years of data puts CVD prevalence among Indian adults at around 11%, rising to 12% in urban areas. CVD was responsible for about 26.6% of all deaths in India as of 2017, up from 15.2% in 1990 — and crucially, it strikes us a full decade earlier than it strikes Western populations. CVDs account for some 45% of deaths in the 40–69 age group: India’s economic engine years. India’s age-standardised CVD death rate of 272 per 100,000 outpaces the global average of 235. South Asia, with a quarter of the world’s people, now carries roughly 60% of the global CVD burden.
These are not just mortality statistics; they are a map of unmet social need. A 45-year-old who has a heart attack in India is often the sole earner. His recovery is shadowed by income loss, catastrophic out-of-pocket spending, depression, and a near-total absence of structured rehabilitation — fewer than a handful of Indian patients ever access formal cardiac rehab. The medicines are prescribed. The life around the medicines is not.
This is exactly the void social prescribing fills. International evidence shows it reduces anxiety and depression, improves quality of life, and — when adherence improves — lowers repeat hospitalisations. For a chronic condition managed largely at home over decades, the social prescription is not adjacent to clinical care. It is clinical care by other means.
What we have seen at HHIF
At Heart Health India Foundation, we have been doing informal social prescribing for years before we had the vocabulary for it. Our work runs on a simple framework — that every patient deserves to be Hugged, Heard, and Helped (our 3H model). In practice, that is social prescribing without the clinical letterhead — and almost all of it is delivered by patients and caregivers, not professionals.
What we have learned is that lived experience is a clinical-grade resource. A survivor who has walked the road has a credibility no pamphlet and few doctors can match. So our peer support runs survivor-to-survivor: fellow cardiac patients act as mentors to the newly diagnosed, sitting with the fear we all remember from our own first weeks. Our patient and caregiver education is led by people who have lived it — our Dil Ke Doubts sessions, where bypass and heart-failure patients put their real questions to a cardiologist or physiotherapist, are routinely moderated by a heart-patient advocate from our own community, not a marketer. And our advocacy is patient-led by design: the people shaping the message are the people who survived the diagnosis, which is the whole point of advocacy by the patients, for the patients.
We have watched a survivor who would not leave his house return to a morning walking group because another survivor — not a doctor — called him every day for a week. We have seen caregivers, led by my co-founder Aditi, pulled back from the edge of burnout simply by being placed in a room with others who understood. We have seen patients who skipped medicines because of cost get connected to assistance, and patients drowning in misinformation get anchored to credible peer knowledge. The clinical system referred these people to nothing because the clinical system had nothing to refer them to. We became the missing referral.
None of this is charity, and framing it as charity is exactly the mistake that keeps it small. A trained survivor-mentor reduces a cardiologist’s follow-up burden. An educated caregiver prevents readmissions. A patient advocate catches the person who would otherwise have abandoned their medication in silence. This is workforce. This is infrastructure. What we lack is structure — the formal pathway WHO describes, where a cardiologist could write the connection into the patient’s plan rather than leaving a survivor’s network to find them by accident. That is the leap India needs to make: from informal goodwill to a designed component of a resilient health system.
The same prescription, read across three Indias
India is not one market or one patient population; it is at least three, and a social prescribing model that ignores this will fail. Borrowing the now-widely-used India1 / India2 / India3 segmentation, the same prescription reads differently in each — and our experience at HHIF has shaped itself around exactly these differences.
India1 — the consuming class
Roughly 140 million people, the digitally fluent top tier. Here the cardiac patient is the urban executive, stented at 48, anxious, over-Googled, and time-poor. The barrier is not access but engagement — this patient trusts data and convenience, and is drowning not in scarcity but in unverified content. This is where much of HHIF’s online community lives: our survivor-led digital groups, awareness campaigns, and bilingual content give this patient a credible, lived-experience counterweight to the noise. The most effective voice in this segment is not an influencer but a patient advocate who has had the same stent and can say so. When we ran our World Heart Day and HCM awareness work, it was this segment that engaged first and amplified it — and many of them, once mentored, became mentors and advocates themselves, which is how a patient community compounds.
India2 — the aspirant class
Around 300 million, semi-urban, UPI-active but value-conscious. This is the heartland of India’s CVD surge, and in many ways the centre of gravity for our day-to-day work. The patient here — a small shopkeeper in Indore, a schoolteacher in a Tier-2 town — has a smartphone and WhatsApp but limited time, money, and rehab access. This is where peer support and caregiver education do their quietest, most consistent work: vernacular and Hinglish peer messaging, fellow patients acting as mentors who check in survivor-to-survivor, and caregivers educating other caregivers. The man who returned to a morning walking group because another survivor called him daily for a week belongs to this India — and the survivor who called him was not paid; he was paying forward his own recovery. Our lifestyle and prevention workshops and caregiver storytelling, much of it deliberately in Hinglish, exist because this is the language in which this segment actually opens up, and because a caregiver who has been there is the most persuasive teacher another caregiver will ever meet.
India3 — the next billion
Roughly a billion people, rural, low-income, often offline. Here the cardiac patient may not even know they have hypertension, and apps are not the channel. This is the segment WHO’s Community Engagement guide is almost written for — health placed literally in the hands of the people, carried by ASHA and ANM workers, self-help groups, and Panchayat-linked health days, because no other channel reliably reaches them. Our peer-support and education instincts point here even where digital tools cannot follow: the model that works is a trained survivor — a “heart mitra,” a patient advocate with lived experience — working alongside a community health worker to do in person what an app does in India1. In a place where the formal system is thinnest, the patient who has survived becomes the most reliable health resource the village has. That is not a stopgap until “real” infrastructure arrives; in much of India3, it is the resilient layer of the health system.
The same underlying scheme — identify, connect, support — written in three different scripts. And a national policy that funded the link-worker role within existing Ayushman Bharat Health and Wellness Centres could turn what organisations like ours do by improvisation into something the system does by design.
How social prescribing changes the future of chronic care
If we get this right, the implications run far beyond cardiology. India’s entire non-communicable disease burden — diabetes, COPD, cancer survivorship, mental health — shares the same structural flaw: a system superb at acute intervention and impoverished at long-term, human, community-rooted support. Social prescribing is the operating system for chronic care that India has never installed.
The future I want to see is one where a discharge summary has two columns: the medical prescription and the social prescription. Where the link worker is as routine a role in a health centre as the pharmacist, and where trained patient-mentors and lived-experience advocates are a recognised, supported cadre rather than an unpaid afterthought. Where an organisation like HHIF is not an accidental safety net but a funded, formal node in the referral pathway. Where we measure a cardiac programme not only by stents placed but by patients reconnected — to movement, to peers, to purpose, to life.
This is the heart of why it matters: a health system held up partly by its own patients is a more resilient system. It does not collapse when specialists are overstretched, because it has distributed the work of long-term support to the people most invested in the outcome. Every survivor who becomes a mentor, every caregiver who becomes an educator, every patient who becomes an advocate adds capacity the system did not have to hire. That is not charity flowing one way; it is a workforce the epidemic itself produces, if only we choose to train and trust it.
The economics favour it too. Connection is cheap; readmission is expensive. A WhatsApp group costs nothing; a second heart attack costs a family its savings and the nation a productive worker in their prime. For a country that cannot afford to medicalise its way out of a 54-million-case CVD epidemic, social prescribing is not the soft option. It is the scalable one.
Join the community
If you are a heart patient, a caregiver, a clinician, or simply someone who cares about heart health, you do not have to wait for the system to catch up. The community already exists, and it is built on exactly the principle this article argues for — patients holding up other patients.
Join the Heart Health India Foundation community → It takes two minutes. You will be connected to our WhatsApp and Facebook groups, receive expert updates from cardiologists, physiotherapists, and dietitians, and find patient stories and support from people who understand the journey because they have lived it. Whether you have just been diagnosed or you are years into recovery and ready to mentor someone else, there is a place for you here — and a role only you can play.
The prescription I wish I’d been given
I survived December 2019. Many do not, and many who do survive the procedure do not survive the years that follow — not because the medicine failed, but because no one prescribed the life around it. The toolkit exists. WHO has written the method. The evidence is in. The three Indias are waiting, each in their own dialect, for a health system that treats the patient and not just the artery.
We have spent a decade proving, one survivor at a time, that connection heals — and that the healers can be the patients themselves. It is time to write that down: formally, at scale, on a prescription pad, and into health policy. Because the cheapest, most underused, most resilient medicine in Indian healthcare is each other.
Heart Health India Foundation operates a patient-led, survivor-driven model of cardiovascular support across India, affiliated with the World Heart Federation and Global Heart Hub. References: WHO, A Toolkit on How to Implement Social Prescribing (2022); WHO, Community Engagement: A Health Promotion Guide for Universal Health Coverage in the Hands of the People; meta-analyses and Global Burden of Disease estimates on CVD prevalence and mortality in India; Blume Ventures / Indus Valley India1-2-3 consumption framework.
